Phase III Randomized Trial of Toremifene vs Tamoxifen in Hormonodependant Advanced Breast Cancer

@article{MillaSantos2001PhaseIR,
  title={Phase III Randomized Trial of Toremifene vs Tamoxifen in Hormonodependant Advanced Breast Cancer},
  author={Alfredo Milla-Santos and Lid{\'o}n Mill{\'a} and Lidon Rallo and Victor Solano},
  journal={Breast Cancer Research and Treatment},
  year={2001},
  volume={65},
  pages={119-124}
}
Purpose. Efficacy and safety of toremifene (TOR) 60mgs/dayly/o.r. was compared with tamoxifen (TAM) 40mgs/dayly/o.r. in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer. Material and methods. The study was a prospective double-blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG… CONTINUE READING